Treatment of primary intraocular melanoma

Author: Damato, Bertil

Source: Expert Review of Anticancer Therapy, Volume 6, Number 4, April 2006 , pp. 493-506(14)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

The treatment of intraocular melanoma has evolved recently. Enucleation has been superseded largely by brachytherapy, proton beam radiotherapy, stereotactic irradiation, trans-scleral local resection, transretinal resection and diode laser phototherapy. Many patients develop metastatic disease, which usually involves the liver and occurs hematogenously. Disseminated disease rarely responds to therapy, and is usually fatal within 1 year of the onset of symptoms. Uveal melanomas develop characteristic chromosomal abnormalities, such as loss of chromosome 3. This is associated with a reduction in the 5-year survival from approximately 95% to less than 50%.

Keywords: eye; melanoma; patient; treatment; uvea; uveal neoplasm

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737140.6.4.493

Publication date: 2006-04-01

More about this publication?

Expert Review of Anticancer Therapy provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites